It is essential for healthcare and pharmaceutical companies to be aware of both critical and non-critical risks when conducting quality clinical trials.
Significant progress is underway in pinpointing treatments and speeding up diagnosis of rare disease, thanks to digital trials and data-driven commercial strategy.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho